• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

UCSF Launches SUGAR Clinical Trial Study to Compare Livongo’s Diabetes Management Program to Standard Diabetes Care

by Fred Pennic 11/14/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

UCSF Launches SUGAR Clinical Trial Study to Compare Livongo’s Diabetes Management Program to Standard Diabetes Care

Applied Health Signals company Livongo Health, today announced the launch of the Study to Understand Gaining Access to Blood Glucose Records (SUGAR), or SUGAR study, a randomized controlled trial in collaboration with the University of California, San Francisco (UCSF). The aim of the clinical trial is to measure the impact of the Livongo for Diabetes program compared to the average standard of care approach to diabetes management utilizing a traditional Bluetooth glucose meter.

SUGAR Study Background/Overview

The randomized controlled clinical trial will randomize 300 people with diabetes to either participate in the Livongo for Diabetes program, which includes a cellular-connected blood glucose meter, unlimited free test strips, remote digital and 1:1 coaching with Certified Diabetes Educators, or receive a Bluetooth glucose meter and unlimited free test strips.

HbA1c is a commonly accepted lab measure for average blood glucose levels over a 90-day period. The HbA1c level can be a marker of the effectiveness of a diabetes management solution. The final results of the study will compare hemoglobin A1c (HbA1c) changes in both populations at six months.

SUGAR Study Participants

SUGAR study participants include:

● People with a diagnosis of type 2 diabetes mellitus on any type of medication

● Adults, age 18 years or older

● People not using a continuous glucose monitoring device nor an insulin pump

● iPhone users with access to data and/or Wi-Fi

Livongo for Diabetes Program

The Livongo for Diabetes program is backed by a team of data scientists who Aggregate, Interpret, Apply and Iterate (AI+AI)™ substantial amounts of health data and information to create actionable, personalized and timely insights, information and nudges to improve how Livongo members experience their chronic condition. “We are interested to see how an innovative solution like Livongo truly impacts people,” said Jenise Wong, MD, Ph.D., Assistant Professor at UCSF and Principal Investigator of the SUGAR study. “By conducting a randomized controlled trial, we can better understand the degree to which innovative offerings improve health outcomes.”

To date, Livongo has demonstrated positive health outcomes, and studies show that Livongo delivers cost savings. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Blood Glucose Monitor, diabetes, Diabetes Management, Diabetes Management Platform, digital diabetes management platform, Livongo Health

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |